Nemaura Successfully Develops Predictive Algorithms and Alarm Functionality for Continuous Glucose Monitor SugarBEAT®
November 07 2018 - 4:00AM
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a
medical technology company developing sugarBEAT® as a non-invasive
affordable and flexible Continuous Glucose Monitor (CGM) for use by
people with diabetes and pre-diabetics, today announced
the successful development of predictive algorithms that will
allow the inclusion of alarms in its sugarBEAT® CGM.
This development is expected
to make sugarBEAT® more appealing to insulin users,
a Total Addressable Market valued at $50Bn. CGM adoption
amongst people with diabetes is minimal and growing rapidly, with
the U.S. the largest single market, with an estimated 2.6% (630,000
users) of all diagnosed diabetics using CGM in 2018, representing
annualized growth of 117%.1
Over the course of the last 14 months Nemaura
Medical has gathered and analysed data stemming
from over 25,000 paired data points between sugarBEAT® and
blood serum samples taken using a venous catheter at 15 minute
intervals for 12 consecutive hours. This analysis has led
to substantial algorithm improvements, including predictive
functionality, allowing alarms to be incorporated into
sugarBEAT®.
Results indicate the alarm functionality can predict
glucose level 5 minutes in advance with 98% accuracy, 10
minutes in advance with 95% accuracy and 15 minutes in advance with
90% accuracy.
SugarBEAT® is anticipated to receive CE Mark approval in the
coming weeks and launch in the United Kingdom shortly
thereafter.
SugarBEAT® has the potential to expand the use of CGM amongst
people with diabetes and pre-diabetics given it is non-invasive and
flexible, as compared to competitor CGMs, which are invasive and
designed to be continuously worn for periods of up to seven days or
longer.
1 PiperJaffray Company Note DXCM Sep 5, 2018
About Nemaura Medical Inc.
Nemaura Medical (NASDAQ:NMRD) is a medical technology company
developing sugarBEAT® as a non-invasive, affordable and flexible
Continuous Glucose Monitor (CGM) designed to help people
with diabetes and pre-diabetics to better manage their glucose
levels. Insulin users can adjunctively use sugarBEAT® when
calibrated with a finger-stick glucose reading.
SugarBEAT® consists of a daily disposable adhesive skin-patch
connected to a rechargeable transmitter, with an app displaying
glucose readings at five minute intervals for periods up to 24
hours.
For more information visit: www.NemauraMedical.com
www.SugarBEAT.com
Cautionary Statement Regarding Forward Looking
Statements
The statements in this press release that are not historical
facts, and may constitute forward-looking statements that are based
on current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to
regulatory approvals and the success of Nemaura Medical’s ongoing
studies, including the safety and efficacy of Nemaura Medical’s
sugarBEAT® system, the failure of future development and
preliminary marketing efforts, Nemaura Medical’s ability to secure
additional commercial partnering arrangements, risks and
uncertainties relating to Nemaura Medical and its partners’ ability
to develop, market and sell sugarBEAT®, the availability of
substantial additional equity or debt capital to support its
research, development and product commercialization activities, and
the success of its research, development, regulatory approval,
marketing and distribution plans and strategies, including those
plans and strategies related to sugarBEAT®. These and other risks
and uncertainties are identified and described in more detail in
Nemaura Medical’s filings with the Securities and Exchange
Commission, including, without limitation, its Annual Report on
Form 10-K for the current year, its Quarterly Reports on Form 10-Q,
and its Current Reports on Form 8-K. Nemaura Medical undertakes no
obligation to publicly update or revise any forward-looking
statements.
Contacts
Nemaura Medical Inc.Bashir TimolChief Business
Officerbashir.timol@nemauramedical.com
RedChip CompaniesVictor
Roberts407-644-4256victor@redchip.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024